President Leonid Beigelman resigns; severance includes 6 months salary, 12 months COBRA

Aligos Therapeutics, Inc.

Dr. Leonid Beigelman, President, resigned effective Nov 20, 2023; entered into separation agreement.
Separation agreement includes general release of claims and standard restrictive covenants.
Severance includes 6 months of current base salary and COBRA continuation at company expense for 12 months.
Agreement to be filed as exhibit to 2023 Form 10-K.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Leonid Beigelman

President

ALGS · Aligos Therapeutics, Inc.

Effective: 2023-11-20
Filed: November 22, 2023, 6:59 PM ET

On November 20, 2023, in connection with the previously disclosed resignation of Leonid Beigelman, President of Aligos Therapeutics, Inc. (the “Company”), the Company and Dr. Beigelman entered into a separation and release agreement

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Leonid Beigelman resigned as President at Aligos Therapeutics, Inc..

Action: resigned
Role: President

Exact text from the filing

On November 20, 2023, in connection with the previously disclosed resignation of Leonid Beigelman, President of Aligos Therapeutics, Inc. (the “Company”), the Company and Dr. Beigelman entered into a separation and release agreement

View on SEC.gov

Aligos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-282236

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.